Physician profile
Ryan Bush
NPI 1780363341
$651.27
in general payments reported to CMS, 2019-2025
14 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.04 · 2024: $252 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.07 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $112.94 | 2024-2025 | Rexulti |
| Indivior INC. | $70.19 | 2024-2025 | Sublocade |
| Braeburn INC. | $50.36 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $48.88 | 2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.30 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $39.64 | 2025 | Auvelity |
| Alkermes, INC. | $37.84 | 2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $34.05 | 2025 | Uzedy |
| Tris Pharma INC | $17.70 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $17.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.62 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $13.81 | 2025 | Cobenfy |
| Orexo US, INC. | $13.37 | 2024 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.